Previous 10 | Next 10 |
Shares of Provention Bio (NASDAQ: PRVB) crashed 28.8% as of the market close on Friday. The huge decline came after a U.S. Food and Drug Administration (FDA) advisory committee voted 10-7 in favor of recommending approval of teplizumab in delaying type 1 diabetes. Investors were...
Gainers: SemiLEDs (LEDS) +49%.Vertex Energy (VTNR) +45%.Organovo (ONVO) +28%.eMagin (EMAN) +24%.Mannatech (MTEX) +21%.Welbilt (WBT) +21%.Yext (YEXT) +19%.MoSys (MOSY) +16%.Embotelladora Andina (AKO-B) +13%.Iterum Therapeutics (ITRM) +17%.Losers: 1847 Goedeker (GOED) -70%.M...
Provention Bio, Inc. (NASDAQ: PRVB) reported that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 10 yes and 7 no on the question, “Does the information provided in the background documents and presentations by th...
Gainers: Organovo (ONVO) +24%, Iterum Therapeutics (ITRM) +16%, Adagene (ADAG) +14%, Freeline Therapeutics (FRLN) +12%, 180 Life Sciences (ATNF) +12%.Losers: Provention Bio (PRVB) -22%, Eton Pharmaceuticals (ETON) -13%, Lannett (LCI) -12%...
1847 Goedeker (GOED) -70% stock seesawed on no specific news; prices $205M equity offering.Provention Bio (PRVB) -16% FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes.Marathon Digital Holdings (MARA) -6%.Riot Blockchain (RIOT) -6%.HP HPQ ...
Provention Bio (PRVB) announces that the FDA's advisory committee voted 10-7, confirming that the benefits of PRVB's drug candidate teplizumab in delaying clinical type 1 diabetes (T1D) outweigh the risks. The recommendation is based on safety and efficacy data from TN-10 Study...
FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D) If approved, teplizumab will be the first disease-modifying therapy in T1D PR Newswire RED BANK, N.J. ...
Provention Bio Stock Trading Halted Today -- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes -- PR Newswire RED BANK, N.J. , May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: P...
Gainers: Owens & Minor (OMI) +25%.Express (EXPR) +23%.PDL Community Bancorp (PDLB) +22%.Takung Art (TKAT) +22%.Assertio Holdings (ASRT) +21%.Asensus Surgical (ASXC) +20%.Lizhi (LIZI) +20%.ReneSola (SOL) +19%.Arcimoto (FUV) +18%.Planet Green (PLAG) +16%.Losers: Lar...
Agilent price target raised by analysts after better than expected Q2 resultsSeveral firms have lifted the price target for Agilent Technologies (A) after the company raised the fiscal 2021 guidance and reported better-than-expected Q2 FY21 earnings. Agilent has added ~5.1% in ...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...